The secret role of microRNAs in cancer stem cell development and potential therapy: A Notch-pathway approach

Frontiers in Oncology

Volumn 5, Issue FEB, 2015, Pages

  Prokopi, Marianna ^a,b   Kousparou, Christina A ^a   Epenetos, Agamemnon A ^a,c,d,e  

^a Bank of Cyprus Group Oncology Centre   (Cyprus)

^b CYPRUS UNIVERSITY OF TECHNOLOGY   (Cyprus)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d Harley Street Specialist Hospital   (United Kingdom)

^e ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Cancer stem cells; Cancer therapeutics; MicroRNAs; miRNA therapeutics; Notch signaling

Indexed keywords

BETA CATENIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JAGGED1; LET 7; MICRORNA; MICRORNA 1; MICRORNA 124; MICRORNA 141; MICRORNA 143; MICRORNA 145; MICRORNA 146A; MICRORNA 15; MICRORNA 16; MICRORNA 199 5P; MICRORNA 200; MICRORNA 200B; MICRORNA 200C; MICRORNA 21; MICRORNA 34A; MICRORNA 34B; MICRORNA 34C; MICRORNA 34C 3P; NOTCH RECEPTOR; PROTEIN BCL 2; PROTEIN P53; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; WNT PROTEIN;

APOPTOSIS; ARTICLE; BIOGENESIS; CANCER GROWTH; CANCER STEM CELL; CARCINOGENESIS; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL INVASION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; LEUKOENCEPHALOPATHY; MESENCHYMAL STEM CELL; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 84923597281     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00389     Document Type: Article

References (67)

1. Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu Rev Cell Dev Biol (2007) 23:675-99. doi: 10.1146/annurev.cellbio.22.010305.104154
2. Colmont CS, Harding KG, Piguet V, Patel GK. Human skin cancer stem cells: a tale of mice and men. Exp Dermatol (2012) 21:576-80. doi:10.1111/j.1600-0625.2012.01533.x
3. Wang Z, Li Y, Banerjee S, Sarkar FH. Exploitation of the Notch signaling pathway as a novel target for cancer therapy. Anticancer Res (2008) 28:3621-30.
4. Joutel A, Tournier-Lasserve E. Notch signalling pathway and human diseases. Semin Cell Dev Biol (1998) 9:619-25. doi:10.1006/scdb.1998.0261
5. Stylianou S, Clarke RB, Brennan K. Aberrant activation of Notch signaling in human breast cancer. Cancer Res (2006) 66:1517-25. doi:10.1158/0008-5472.CAN-05-3054
6. Wharton KA, Johansen KM, Xu T, Artavanis-Tsakonas S. Nucleotide sequence from the neurogenic locus Notch implies a gene product that shares homology with proteins containing EGF-like repeats. Cell (1985) 43:567-81. doi:10.1016/0092-8674(85)90229-6
7. Artavanis-Tsakonas S, Matsuno K, Fortini ME. Notch signaling. Science (1995) 268:225-32. doi:10.1126/science.7716513
8. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell (2009) 137:216-33. doi:10.1016/j.cell.2009.03.045
9. Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer (2011) 11:338-51. doi:10.1038/nrc3035
10. Reynolds TC, Smith SD, Sklar J. Analysis of DNA surrounding the breakpoints of chromosomal translocations involving the beta T cell receptor gene in human lymphoblastic neoplasms. Cell (1987) 50:107-17. doi:10.1016/0092-8674(87)90667-2
11. Wang Z, Li Y, Banerjee S, Sarkar FH. Emerging role of Notch in stem cells and cancer. Cancer Lett (2009) 279:8-12. doi:10.1016/j.canlet.2008.09.030
12. Dotto GP. Notch tumor suppressor function. Oncogene (2008) 27:5115-23. doi:10.1038/onc.2008.225
13. Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort M, et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet (2003) 33:416-21. doi:10.1038/ng1099
14. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res (2005) 65:8530-7. doi:10.1158/0008-5472.CAN-05-1069
15. Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL, et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res (2004) 64:6854-7. doi:10.1158/0008-5472.CAN-04-2500
16. Wang Z, Li Y, Banerjee S, Kong D, Ahmad A, Nogueira V, et al. Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways. J Cell Biochem (2010) 109:726-36. doi:10.1002/jcb.22451
17. Reedijk M, Odorcic S, Zhang H, Chetty R, Tennert C, Dickson BC, et al. Activation of Notch signaling in human colon adenocarcinoma. Int J Oncol (2008) 33:1223-9. doi:10.3892/ijo_00000112
18. Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y, Sarkar FH. Down-regulation of Notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res (2006) 66:2778-84. doi:10.1158/0008-5472.CAN-05-4281
19. Hassan KA, Wang L, Korkaya H, Chen G, Maillard I, Beer DG, et al. Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin Cancer Res (2013) 19:1972-80. doi:10.1158/1078-0432.CCR-12-0370
20. Wang K, Wu X, Wang J, Huang J. Cancer stem cell theory: therapeutic implications for nanomedicine. Int J Nanomedicine (2013) 8:899-908. doi:10.2147/IJN.S38641
21. Grego-Bessa J, Diez J, Timmerman L, de la Pompa JL. Notch and epithelial-mesenchyme transition in development and tumor progression: another turn of the screw. Cell Cycle (2004) 3:718-21. doi:10.4161/cc.3.6.949
22. Leong KG, Niessen K, Kulic I, Raouf A, Eaves C, Pollet I, et al. Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. J Exp Med (2007) 204:2935-48. doi:10.1084/jem.20071082
23. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell (2009) 139:871-90. doi:10.1016/j.cell.2009.11.007
24. Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res (2009) 69:7569-76. doi:10.1158/0008-5472.CAN-09-0529
25. Garzia L, Andolfo I, Cusanelli E, Marino N, Petrosino G, De Martino D, et al. MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS One (2009) 4:e4998. doi:10.1371/journal.pone.0004998
26. Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA (2004) 10:1957-66. doi:10.1261/rna.7135204
27. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet (2004) 5:522-31. doi:10.1038/nrg1415
28. Iorio MV, Croce CM. Causes and consequences of microRNA dysregulation. Cancer J (2012) 18:215-22. doi:10.1097/PPO.0b013e318250c001
29. O'Hara SP, Mott JL, Splinter PL, Gores GJ, LaRusso NF. MicroRNAs: key modulators of posttranscriptional gene expression. Gastroenterology (2009) 136:17-25. doi:10.1053/j.gastro.2008.11.028
30. Di Leva G, Croce CM. miRNA profiling of cancer. Curr Opin Genet Dev (2013) 23:3-11. doi:10.1016/j.gde.2013.01.004
31. Deng S, Calin GA, Croce CM, Coukos G, Zhang L. Mechanisms of microRNA deregulation in human cancer. Cell Cycle (2008) 7:2643-6. doi:10.4161/cc.7.17.6597
32. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 101:2999-3004. doi:10.1073/pnas.0307323101
33. Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, Bersani S, et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol (2006) 24:4677-84. doi:10.1200/JCO.2005.05.5194
34. Pan X, Wang ZX, Wang R. MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol Ther (2010) 10:1224-32. doi:10.4161/cbt.10.12.14252
35. Bian S, Sun T. Functions of noncoding RNAs in neural development and neurological diseases. Mol Neurobiol (2011) 44:359-73. doi:10.1007/s12035-011-8211-3
36. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 6:857-66. doi:10.1038/nrc1997
37. Hammond SM. RNAi, microRNAs, and human disease. Cancer Chemother Pharmacol (2006) 58(Suppl 1):s63-8. doi:10.1007/s00280-006-0318-2
38. Mishra PJ, Merlino G. MicroRNA reexpression as differentiation therapy in cancer. J Clin Invest (2009) 119:2119-23. doi:10.1172/JCI40107
39. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A (2005) 102:13944-9. doi:10.1073/pnas.0506654102
40. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 99:15524-9. doi:10.1073/pnas.242606799
41. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. A microRNA component of the p53 tumour suppressor network. Nature (2007) 447:1130-4. doi:10.1038/nature05939
42. Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One (2009) 4:e6816. doi:10.1371/journal.pone.0006816
43. He C, Xiong J, Xu X, Lu W, Liu L, Xiao D, et al. Functional elucidation of MiR-34 in osteosarcoma cells and primary tumor samples. Biochem Biophys Res Commun (2009) 388:35-40. doi:10.1016/j.bbrc.2009.07.101
44. Poellinger L, Lendahl U. Modulating Notch signaling by pathway-intrinsic and pathway-extrinsic mechanisms. Curr Opin Genet Dev (2008) 18:449-54. doi:10.1016/j.gde.2008.07.013
45. Wu Z, Wu Y, Tian Y, Sun X, Liu J, Ren H, et al. Differential effects of miR-34c-3p and miR-34c-5p on the proliferation, apoptosis and invasion of glioma cells. Oncol Lett (2013) 6:1447-52. doi:10.3892/ol.2013.1579
46. Wang Z, Zhang Y, Li Y, Banerjee S, Liao J, Sarkar FH. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther (2006) 5:483-93. doi:10.1158/1535-7163.MCT-05-0299
47. Kashat M, Azzouz L, Sarkar SH, Kong D, Li Y, Sarkar FH. Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness. Am J Transl Res (2012) 4:432-42.
48. Brabletz S, Bajdak K, Meidhof S, Burk U, Niedermann G, Firat E, et al. The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J (2011) 30:770-82. doi:10.1038/emboj.2010.349
49. Vallejo DM, Caparros E, Dominguez M. Targeting Notch signalling by the conserved miR-8/200 microRNA family in development and cancer cells. EMBO J (2011) 30:756-69. doi:10.1038/emboj.2010.358
50. Wang Z, Banerjee S, Ahmad A, Li Y, Azmi AS, Gunn JR, et al. Activated K-ras and INK4a/Arf deficiency cooperate during the development of pancreatic cancer by activation of Notch and NF-kappaB signaling pathways. PLoS One (2011) 6:e20537. doi:10.1371/journal.pone.0020537
51. Ohashi S, Natsuizaka M, Naganuma S, Kagawa S, Kimura S, Itoh H, et al. A NOTCH3-mediated squamous cell differentiation program limits expansion of EMT-competent cells that express the ZEB transcription factors. Cancer Res (2011) 71:6836-47. doi:10.1158/0008-5472.CAN-11-0846
52. De Antonellis P, Liguori L, Falanga A, Carotenuto M, Ferrucci V, Andolfo I, et al. MicroRNA 199b-5p delivery through stable nucleic acid lipid particles (SNALPs) in tumorigenic cell lines. Naunyn Schmiedebergs Arch Pharmacol (2013) 386:287-302. doi:10.1007/s00210-013-0837-4
53. Wang X, Lu H, Li T, Yu L, Liu G, Peng X, et al. Kruppel-like factor 8 promotes tumorigenic mammary stem cell induction by targeting miR-146a. Am J Cancer Res (2013) 3:356-73.
54. Wang Z, Li Y, Ahmad A, Azmi AS, Banerjee S, Kong D, et al. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta (2010) 1806:258-67. doi:10.1016/j.bbcan.2010.06.001
55. Furukawa S, Kawasaki Y, Miyamoto M, Hiyoshi M, Kitayama J, Akiyama T. The miR-1-NOTCH3-Asef pathway is important for colorectal tumor cell migration. PLoS One (2013) 8:e80609. doi:10.1371/journal.pone.0080609
56. Mosquera JM, Sboner A, Zhang L, Chen CL, Sung YS, Chen HW, et al. Novel MIR143-NOTCH fusions in benign and malignant glomus tumors. Genes Chromosomes Cancer (2013) 52:1075-87. doi:10.1002/gcc.22102
57. Pang RT, Leung CO, Ye TM, Liu W, Chiu PC, Lam KK, et al. MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis (2010) 31:1037-44. doi:10.1093/carcin/bgq066
58. Bu P, Chen KY, Chen JH, Wang L, Walters J, Shin YJ, et al. A microRNA miR-34a-regulated bimodal switch targets Notch in colon cancer stem cells. Cell Stem Cell (2013) 12:602-15. doi:10.1016/j.stem.2013.03.002
59. Lujambio A, Calin GA, Villanueva A, Ropero S, Sanchez-Cespedes M, Blanco D, et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A (2008) 105:13556-61. doi:10.1073/pnas.0803055105
60. Yang YP, Chien Y, Chiou GY, Cherng JY, Wang ML, Lo WL, et al. Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. Biomaterials (2012) 33:1462-76. doi:10.1016/j.biomaterials.2011.10.071
61. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell (2009) 137:1005-17. doi:10.1016/j.cell.2009.04.021
62. Ratajczak J, Miekus K, Kucia M, Zhang J, Reca R, Dvorak P, et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia (2006) 20:847-56. doi:10.1038/sj.leu.2404132
63. Prokopi M, Pula G, Mayr U, Devue C, Gallagher J, Xiao Q, et al. Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures. Blood (2009) 114:723-32. doi:10.1182/blood-2009-02-205930
64. Rayner KJ, Hennessy EJ. Extracellular communication via microRNA: lipid particles have a new message. J Lipid Res (2013) 54:1174-81. doi:10.1194/jlr.R034991
65. Prokopi M, Epenetos A, Anayiotos A, Pitsillides C, Kapnisis K, Kousparou C. Therapeutic miRNAs targeted selectively to tumors by mesenchymal stem cell derived microparticles. Cancer Res (2014) 74:1977. doi:10.1158/1538-7445.AM2014-1977
66. Dai LJ, Moniri MR, Zeng ZR, Zhou JX, Rayat J, Warnock GL. Potential implications of mesenchymal stem cells in cancer therapy. Cancer Lett (2011) 305:8-20. doi:10.1016/j.canlet.2011.02.012
67. Fritz V, Jorgensen C. Mesenchymal stem cells: an emerging tool for cancer targeting and therapy. Curr Stem Cell Res Ther (2008) 3:32-42. doi:10.2174/157488808783489462